Stryker names Kevin Lobo as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Kevin Lobo will now serve as Stryker's president and CEO

Stryker ($SYK) has a new CEO 7 months after Stephen MacMillan resigned under a cloud of rumors that he may have been forced out for dating an ex-employee. The Michigan devicemaker said Kevin Lobo is now both the company's president and CEO. He moves up the ranks fairly quickly, most recently having served as president of Stryker Orthopedics. Before that, he ran Johnson & Johnson's ($JNJ) Medical Products division in Canada and was also head of Ethicon Endosurgery. Story

Kevin Lobo--Stryker

Lobo now serves as the company's president and CEO.

Frances Heller--Bristol-Myers Squibb

Heller now serves as senior vice president of business development.

Felix W. Frueh--Third Rock Ventures

Frueh was appointed entrepreneur-in-residence.


> Oncolytics Biotech ($ONCY) appointed Alan Tuchman to the role of chief medical officer and senior vice president of clinical and medical development. Release

> GW Pharmaceuticals appointed Chris Tovey as chief operating officer. Release

> Axelar appointed Carl Harald Janson as chief executive officer. Release

> Accelrys ($ACCL) appointed former Siemens ($SI) executive Leif Pederson as its senior vice president of marketing, product management and corporate development. Release

> Tolera Therapeutics appointed Linda C. Hogan as vice president of business development. Release

> Third Rock Ventures appointed personalized medicine expert Felix W. Frueh as entrepreneur-in-residence. News

> Response Genetics ($RGDX) appointed James Wynne as vice president of sales and marketing. Release

> Affymax ($AFFY) appointed Karin L. Walker as vice president of finance and chief accounting officer. Release

> Sunesis Pharmaceuticals ($SNSS) appointed Deborah A. Thomas as vice president of regulatory affairs, and Gene C. Jamieson as vice president of chemistry, manufacturing and controls. Release

> Emergent Technologies appointed Kris Looney as president and Brian Windsor as executive vice president and director of life sciences. Release

> Verinata Health appointed Vance Vanier as president; Keith Jones as senior vice president of research and development; and Suchetta Bhatt as vice president of genetics. Release

> RetroSense Therapeutics named Steven Bramer as chief development officer. Release

> Sialix appointed Jeff Behrens as CEO and Julie Hermann as director of business development and operations. Release

> Alliqua appointed James Sapirstein as CEO. Release


> Bristol-Myers Squibb ($BMY) appointed Frances Heller as senior vice president of business development, effective Oct. 1. Release

> Reckitt Benckiser named Tiffany McClaud to the position of consumer healthcare marketing director. Story

> Sanofi ($SNY) appointed Paul Chew as senior vice president, chief medical officer and head of global medical affairs as of Jan. 1. Article

Pharma Manufacturing

> Novasep appointed Patrick Glaser, who has been in charge of the Novasep Synthesis division since May 2010, as president and CEO. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.